Cytotoxic T lymphocytes for the treatment of viral infections and posttransplant lymphoproliferative disorders in transplant recipients

Daria Pagliara, Barbara Savoldo

Research output: Contribution to journalArticle

Abstract

Purpose of Review: The continuous and successful expansion of organ transplants is unfortunately associated with increased incidence of severe opportunistic viral infections and Epstein-Barr virus (EBV)-related lymphomas secondary to immunosuppression. Here, we review the strengths and limitations of T-cell-based strategies used to treat viral infections in immunocompromised individuals. Recent Findings: While current antiviral drugs are often suboptimal because of associated toxicities, a promising approach in the management of infections with viruses like cytomegalovirus (CMV), adenovirus (AdV) and EBV is the adoptive transfer of T cells targeting these viruses that can be directly isolated from the peripheral blood of the donor or expanded ex vivo prior to infusions in patients. Summary: T-cell-based immunotherapies are now being included in the clinical practice of transplant recipients to prevent and treat infections and complications associated with CMV, AdV and EBV. Improvement of current limitations will enable the extension of these approaches to all patients at risk and to other clinically relevant viruses and pathogens that are emerging as significant complications for immunocompromised patients.

Original languageEnglish
Pages (from-to)431-437
Number of pages7
JournalCurrent Opinion in Infectious Diseases
Volume25
Issue number4
DOIs
Publication statusPublished - Aug 2012

Fingerprint

Lymphoproliferative Disorders
Cytotoxic T-Lymphocytes
Virus Diseases
Human Herpesvirus 4
Cytomegalovirus
T-Lymphocytes
Adenoviridae
Viruses
Adoptive Transfer
Opportunistic Infections
Immunocompromised Host
Blood Donors
Immunotherapy
Immunosuppression
Antiviral Agents
Lymphoma
Therapeutics
Transplants
Incidence
Infection

Keywords

  • adenovirus
  • cytomegalovirus
  • cytotoxic T cells
  • Epstein-Barr virus

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

@article{39b98ec0dd04469cb13f12fd72d83f25,
title = "Cytotoxic T lymphocytes for the treatment of viral infections and posttransplant lymphoproliferative disorders in transplant recipients",
abstract = "Purpose of Review: The continuous and successful expansion of organ transplants is unfortunately associated with increased incidence of severe opportunistic viral infections and Epstein-Barr virus (EBV)-related lymphomas secondary to immunosuppression. Here, we review the strengths and limitations of T-cell-based strategies used to treat viral infections in immunocompromised individuals. Recent Findings: While current antiviral drugs are often suboptimal because of associated toxicities, a promising approach in the management of infections with viruses like cytomegalovirus (CMV), adenovirus (AdV) and EBV is the adoptive transfer of T cells targeting these viruses that can be directly isolated from the peripheral blood of the donor or expanded ex vivo prior to infusions in patients. Summary: T-cell-based immunotherapies are now being included in the clinical practice of transplant recipients to prevent and treat infections and complications associated with CMV, AdV and EBV. Improvement of current limitations will enable the extension of these approaches to all patients at risk and to other clinically relevant viruses and pathogens that are emerging as significant complications for immunocompromised patients.",
keywords = "adenovirus, cytomegalovirus, cytotoxic T cells, Epstein-Barr virus",
author = "Daria Pagliara and Barbara Savoldo",
year = "2012",
month = "8",
doi = "10.1097/QCO.0b013e3283551dd3",
language = "English",
volume = "25",
pages = "431--437",
journal = "Current Opinion in Infectious Diseases",
issn = "0951-7375",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Cytotoxic T lymphocytes for the treatment of viral infections and posttransplant lymphoproliferative disorders in transplant recipients

AU - Pagliara, Daria

AU - Savoldo, Barbara

PY - 2012/8

Y1 - 2012/8

N2 - Purpose of Review: The continuous and successful expansion of organ transplants is unfortunately associated with increased incidence of severe opportunistic viral infections and Epstein-Barr virus (EBV)-related lymphomas secondary to immunosuppression. Here, we review the strengths and limitations of T-cell-based strategies used to treat viral infections in immunocompromised individuals. Recent Findings: While current antiviral drugs are often suboptimal because of associated toxicities, a promising approach in the management of infections with viruses like cytomegalovirus (CMV), adenovirus (AdV) and EBV is the adoptive transfer of T cells targeting these viruses that can be directly isolated from the peripheral blood of the donor or expanded ex vivo prior to infusions in patients. Summary: T-cell-based immunotherapies are now being included in the clinical practice of transplant recipients to prevent and treat infections and complications associated with CMV, AdV and EBV. Improvement of current limitations will enable the extension of these approaches to all patients at risk and to other clinically relevant viruses and pathogens that are emerging as significant complications for immunocompromised patients.

AB - Purpose of Review: The continuous and successful expansion of organ transplants is unfortunately associated with increased incidence of severe opportunistic viral infections and Epstein-Barr virus (EBV)-related lymphomas secondary to immunosuppression. Here, we review the strengths and limitations of T-cell-based strategies used to treat viral infections in immunocompromised individuals. Recent Findings: While current antiviral drugs are often suboptimal because of associated toxicities, a promising approach in the management of infections with viruses like cytomegalovirus (CMV), adenovirus (AdV) and EBV is the adoptive transfer of T cells targeting these viruses that can be directly isolated from the peripheral blood of the donor or expanded ex vivo prior to infusions in patients. Summary: T-cell-based immunotherapies are now being included in the clinical practice of transplant recipients to prevent and treat infections and complications associated with CMV, AdV and EBV. Improvement of current limitations will enable the extension of these approaches to all patients at risk and to other clinically relevant viruses and pathogens that are emerging as significant complications for immunocompromised patients.

KW - adenovirus

KW - cytomegalovirus

KW - cytotoxic T cells

KW - Epstein-Barr virus

UR - http://www.scopus.com/inward/record.url?scp=84863718403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863718403&partnerID=8YFLogxK

U2 - 10.1097/QCO.0b013e3283551dd3

DO - 10.1097/QCO.0b013e3283551dd3

M3 - Article

C2 - 22614521

AN - SCOPUS:84863718403

VL - 25

SP - 431

EP - 437

JO - Current Opinion in Infectious Diseases

JF - Current Opinion in Infectious Diseases

SN - 0951-7375

IS - 4

ER -